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Background. Acute myeloid leukemia (AML) is a genetically heteroge-
neous disease. While approximately half of AML patients have at least
one chromosomal aberration, the other half classifies as cytogenetical-
ly normal (CN-AML). In CN-AML patients an increasing number of
recurring somatic mutations have been identified during the last decade.
Despite their pathological and prognostic relevance, none of these muta-
tions are sufficient to cause AML on their own. Furthermore, in approx-
imately one quarter of the CN-AML patients none of the known muta-
tions can be detected. Aims. To identify novel mutations in AML by
transcriptome sequencing using a next generation sequencing machine.
Design and Methods. The term transcriptome summarizes all mRNA tran-
scripts present in the cells from a certain patient sample. To identify
tumor-specific somatic coding mutations, we sequenced the transcrip-
tome of a CN-AML and a remission sample from the same patient using
an Illumina GAII machine. Poly-A selected, fragmented RNA was used
to synthesize double stranded cDNA, which was then sequenced. SNPs
were called with the MAQ software. Results. We generated 20.4 and
15.6 million 32 bp paired-end reads of the CN-AML and remission sam-
ple, respectively, which mapped to exons of UCSC genes. 8.9% of reads
for the AML and 5.0% reads of the remission sample mapped to inter-
genic regions. Of the 11,178 transcripts with a higher expression than
60 reads per gene (corresponding to approximately 1 transcript per cell),
we sequenced 5,911 with an average coverage of greater than seven. By
comparing the 63,159 SNPs discovered in the CN-AML sample with
the remission sample, we identified 5 non-synonymous mutations not
present in either the remission sample or in dbSNP. One of these point
mutations affected the RUNX1 gene which forms a well known fusion
gene in AML (RUNX1/RUNX1T1) and is a known mutational target in
AML. The second mutation affected a gene which encodes a RUNX1
interacting protein, and a third mutation was found in the cellular
homolog of a viral oncogene. The two other mutations occurrred in a
phospholipase gene and a nuclear chaperon gene. The five genes iden-
tified as mutational targets are currently studied in a larger patient cohort
of 200 patients with normal karyotype in order to determine the fre-
quency of mutations in these genes. Conclusions. Transcriptome sequenc-
ing of AML patients is a pioneering application of the latest sequencing
technology that may allow the unbiased detecting and understanding of
the majority of genetic lesions that contribute to the onset and progres-
sion of AML. For mutation screening in the coding regions of expressed
genes, whole transcriptome sequencing is currently 5-10 times faster
and more cost effective than whole genome sequencing. 
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Acute myeloid leukemias (AML) are clonal malignant disorders that
result from multiple genetic alterations in normal hematopoietic stem
cells. In recent years, several genetic markers with prognostic impact in
AML have been identified, permitting a better understanding of the biol-
ogy of this disease and, in some cases, providing targets for molecular
therapies. However, the outcome of older patients with AML has not
improved in the last three decades, due to both patient-specific and dis-
ease-specific factors. Here, we describe a novel t(12;18)(p13;q12) involv-
ing ETV6 in a patient with AML. The translocation resulted in no func-
tional fusion gene, indicating that a different mechanism might be act-
ing. The SETBP1 gene (18q12), located close to the breakpoint, was
overexpressed in the patient, suggesting that expression of this gene
was upregulated by the translocation. Overexpression (OE) of SETBP1
through retroviral insertion has been reported to confer a growth advan-
tage in hematopoietic progenitor cells, and SETBP1 interacts specifical-
ly with the SET protein, a potent inhibitor of PP2A; however, the role
of this gene at the molecular level remained unknown. We demonstrate
that SETBP1 OE leads to higher levels of SET due to formation of a
SETBP1-SET heterodimer that protects SET of the protease activity,
increasing the amount of full-length SET protein of 39 KDa, and decreas-
ing the shorter SET processed forms. We also observed the formation
of a SETBP1-SET-PP2A complex that, eventually, results in PP2A inhibi-
tion. Furthermore, the deregulation of PP2A activity promotes prolifer-
ation of the myeloid leukemic cells. We also analyzed the prevalence of
SETBP1 OE in a series of 192 patients with AML at diagnosis. SETBP1
was overexpressed in 28% of patients with AML, and it was associat-
ed with unfavorable cytogenetic prognostic group, monosomy 7, and
EVI1 OE (p<0.01). We found a significant shorter overall survival (OS)
in patients with SETBP1 OE. The impact prognosis was especially
remarkable in the group of patients older than 60 years in both OS
(p=0.015) and event free survival (p=0.015). In conclusion, our results
show a novel leukemogenic mechanism: SETBP1 overexpression would
lead to the formation of a SETBP1-SET-PP2A complex that increases the
amount of full-length SET protein, resulting in PP2A inhibition and,
therefore, promoting the proliferation of the cells. Moreover, we have
shown that SETBP1 overexpression is a recurrent molecular event with
prognostic impact in AML, especially in the subgroup of elderly patients.
Advanced age is the most important prognostic factor for determining
outcome in AML, therefore, it is important to identify genetic markers
that could categorize cases within this subgroup. Systematic molecular
genetic studies in AML patients not only are useful for the evaluation of
biomarkers for prognostication, but also for the identification of predic-
tive factors for response to novel therapies. Our data suggest that
SETBP1 overexpression could be a predictive factor for response to PP2A
activators such as FTY720, which has been proposed as a new alterna-
tive for treating blast crisis CML and Philadelphia chromosome-positive
ALL.
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Background. The PIM1 and PIM2 serine/threonine kinases are overex-
pressed in most human hematological malignancies. By expression of
siRNAs or dominant-negative mutants, we have previously shown that
PIM kinases are important for proliferation and survival of hematopoi-
etic cells transformed by oncogenic protein tyrosine kinases such as the
FLT3-ITD mutant associated with acute myeloid leukemia (AML). Aims.
To study the role of PIM kinases in FLT3-ITD mediated leukemogene-
sis. Design and Methods: Reconstitution assays with FLT3-ITD express-
ing PIM-/- bone marrow cells were performed. We also modulated the
function of PIM kinases in cell lines by small molecule PIM inhibitors and
isoform-specific siRNAs. in vitro kinase assays as well as masspectrom-
etry was used to characterize putative PIM phosphorylation sites. Results.
Unexpectedly, bone marrow cells deficient for PIM1 failed to reconsti-
tute lethally irradiated wild-type recipients, whereas, the absence of
PIM2 did not interfere with the induction of a FLT3-ITD-mediated
leukemia-like disease. PIM1-/- bone marrow cells were impaired in ear-
ly homing to bone marrow and spleen. PIM1-/- but not PIM2-/- bone
marrow cells displayed decreased surface expression of the CXCR4
receptor and were defective in migration towards the CXCL12 ligand.
By blocking PIM1 function or re-expression in PIM1-/- bone marrow
cells, we found that PIM1 activity was essential for proper CXCR4 sur-
face expression and migration towards CXCL12. By expression of wild-
type and mutant GST-CXCR4-C-terminal mutants we identified Serine
339 in the CXCR4 intracellular domain as being phosphorylated by
PIM1 and essential for proper recycling of the receptor to the surface. In
addition, expression of S339 CXCR4 mutants in cell lines functionally
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